Pharma Biotech Expo 2022

Recombinant DNA Technology in Pharma and Medicine

The recombinant production of therapeutic proteins for human diseases is currently the largest source of innovation in the pharmaceutical industry

The global recombinant DNA technology market is expected to reach USD 844.6 billion by 2025, according to a new report by Grand View Research, Inc. Success of genetically engineered human insulin in diabetes treatment has triggered the development of many other recombinant therapeutics and drugs. This has translated to the huge success of Recombinant DNA technology. This technology has offered significant prospects for elucidating the gap between disease and its effective treatment.

Widespread successful application of this technique in veterinary product development, genetically modified crop development, bio pesticides & biofuel production, and gene therapy, are expected to spur the adoption of this technology throughout the forecast period. Use of Genetically Modified products, such as Genetically Modified animals, developed using rDNA method are found to be indispensable to accelerate medical research. Furthermore, more than 3000 scientific studies have been carried out to assess the GM products safety in context to its impact on human health and environment.

 According to Statistics MRC, the Global Recombinant DNA Technology Market is accounted for $499.8 million in 2016 and expected to grow at a CAGR of 6.9% to reach $799.9 million by 2023.